Finerenone (Synonyms: BAY 94-8862)

Name: Finerenone
Brand: MedChemExpress
SKU: HY-111372
Rating: 5.0 (7 reviews)

Cat. No.: HY-111372 Pureza: 99.91%: Ficha de datos
COA

SDS
Instrucciones de manejo
FAQs
Technical Support

Finerenone (BAY 94-8862) is a third-generation, selective, and orally active nonsteroidal mineralocorticoid receptor (MR) antagonist (IC₅₀ = 18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (> 500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease.

Para uso exclusivo en investigación. No vendemos a pacientes.

No. CAS : 1050477-31-0

Tamaño	Stock	Cantidad
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	En stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	En stock	Estimated Time of Arrival: December 31
Solid
5 mg	En stock	Estimated Time of Arrival: December 31
10 mg	En stock	Estimated Time of Arrival: December 31
25 mg	En stock	Estimated Time of Arrival: December 31
50 mg	En stock	Estimated Time of Arrival: December 31
100 mg	En stock	Estimated Time of Arrival: December 31
200 mg	Obtener un presupuesto
500 mg	Obtener un presupuesto

or Consulta para venta a granel

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Revisión del cliente

Based on 7 publication(s) in Google Scholar

Other Forms of Finerenone:

7 Publications Citing Use of MCE Finerenone

•Gene Rep. 2025 Oct 4.

In Vivo Efficacy Study

Histological Imaging/Staining

Cell Imaging/Staining

RT-PCR

: Finerenone purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Apr:139:156473.; Finerenone (10 mg/kg; p.o. daily from the fifth week) protects against low body weight in diabetic kidney disease mice.

: Finerenone purchased from MedChemExpress. Usage Cited in: Nature. 2023 Feb;614(7947):326-333. [Abstract]; Finerenone (1 μM; 24 h) increases Il6, Il1b, and Ccl2 gene expression in primary mouse astrocytes activated in vitro with 1 ng/mL of IL-1β and TNFα, and (1 μM; 4 h) also boosts Xbp1 splicing.

: Finerenone purchased from MedChemExpress. Usage Cited in: Redox Biol. 2023 Dec:68:102946.; Effect of Finerenone (3 mg/kg/d; p.o.for 12 weeks) on kidney morphology alterations in HFD/STZ-induced T2DM mice's kidneys.

: Finerenone purchased from MedChemExpress. Usage Cited in: Redox Biol. 2023 Dec:68:102946.; Effect of Finerenone (3 mg/kg/d; p.o.for 12 weeks) on serum creatinine and urinary ACR alterations in HFD/STZ-induced T2DM mice's kidneys.

: Finerenone purchased from MedChemExpress. Usage Cited in: Redox Biol. 2023 Dec:68:102946.; PAS staining provides representative histology of the renal cortex after Finerenone (3 mg/kg/d; p.o.for 12 weeks) treatment in HFD/STZ-induced T2DM mice's kidneys.

: Finerenone purchased from MedChemExpress. Usage Cited in: Redox Biol. 2023 Dec:68:102946.; Finerenone (5 mM; 24 h) alleviates the overactivation of MR via PI3K/Akt/eNOS signaling pathway in HK-2 cells treated with HG.

: Finerenone purchased from MedChemExpress. Usage Cited in: Redox Biol. 2023 Dec:68:102946.; Effect of Finerenone (5 mM; 24 h) on dysfunctional mitochondria, mitoROS generation, and HK-2 cell apoptosis.

Recomendaciones destacadas

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Actividad biológica
Pureza y Documentación
Referencias
Revisión del cliente

Descripciòn

Cellular Effect

Cell Line	Type	Value	Description	References
CHO-K1	IC₅₀	16 1 Compound: 3	Antagonist activity against human mineralocorticoid receptor expressed in CHOK1 cells after 10 to 30 mins by luciferase reporter gene assay Antagonist activity against human mineralocorticoid receptor expressed in CHOK1 cells after 10 to 30 mins by luciferase reporter gene assay	[PMID: 22866979]
CHO-K1	IC₅₀	16 1 Compound: 3	Antagonist activity against human mineralocorticoid receptor expressed in CHOK1 cells after 10 to 30 mins by luciferase reporter gene assay Antagonist activity against human mineralocorticoid receptor expressed in CHOK1 cells after 10 to 30 mins by luciferase reporter gene assay	[PMID: 22866979]
CHO-K1	IC₅₀	16 1 Compound: 3	Antagonist activity against human mineralocorticoid receptor expressed in CHOK1 cells after 10 to 30 mins by luciferase reporter gene assay Antagonist activity against human mineralocorticoid receptor expressed in CHOK1 cells after 10 to 30 mins by luciferase reporter gene assay	[PMID: 22866979]
HEK-293T	IC₅₀	58 1 Compound: S-1p	Antagonist activity at Gal4-fused human MR LBD expressed in HEK293T cells assessed as inhibition of aldosterone-induced transactivation activity after 16 hrs by luciferase reporter gene assay Antagonist activity at Gal4-fused human MR LBD expressed in HEK293T cells assessed as inhibition of aldosterone-induced transactivation activity after 16 hrs by luciferase reporter gene assay	[PMID: 28051871]
HEK-293T	IC₅₀	58 1 Compound: S-1p	Antagonist activity at Gal4-fused human MR LBD expressed in HEK293T cells assessed as inhibition of aldosterone-induced transactivation activity after 16 hrs by luciferase reporter gene assay Antagonist activity at Gal4-fused human MR LBD expressed in HEK293T cells assessed as inhibition of aldosterone-induced transactivation activity after 16 hrs by luciferase reporter gene assay	[PMID: 28051871]
HEK-293T	IC₅₀	58 1 Compound: S-1p	Antagonist activity at Gal4-fused human MR LBD expressed in HEK293T cells assessed as inhibition of aldosterone-induced transactivation activity after 16 hrs by luciferase reporter gene assay Antagonist activity at Gal4-fused human MR LBD expressed in HEK293T cells assessed as inhibition of aldosterone-induced transactivation activity after 16 hrs by luciferase reporter gene assay	[PMID: 28051871]

In Vivo

Finerenone (BAY 94-8862) lowers albuminuria by >40% and significantly reduces systolic blood pressure (SBP) in Munich Wistar Fr mter (MWF) rat^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Twelve-week-old MWF rat^[1]
Dosage:	10 mg/kg
Administration:	P.o.; daily for 4 weeks
Result:	Significantly reduced SBP in MWF rats; led to a significant reduction (>40%) in albuminuria in the MWF model.

Animal Model:	Twelve-week-old MWF rat^[1]
Dosage:	10 mg/kg
Administration:	P.o.; daily for 4 weeks
Result:	Significantly reduced SBP in MWF rats; led to a significant reduction (>40%) in albuminuria in the MWF model.

Ensayo clínico

Peso molecular

378.42

Fòrmula

C₂₁H₂₂N₄O₃

No. CAS

1050477-31-0

Appearance

Solid

Color

White to off-white

SMILES

O=C(C1=C(C)NC2=C(C(OCC)=NC=C2C)[C@@H]1C3=CC=C(C#N)C=C3OC)N

Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvente y solubilidad

In Vitro:

DMSO : 70 mg/mL (184.98 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.6426 mL	13.2128 mL	26.4257 mL
5 mM	0.5285 mL	2.6426 mL	5.2851 mL
10 mM	0.2643 mL	1.3213 mL	2.6426 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculadora de molaridad
Calculadora de dilución

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (5.50 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.
Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.93 mg/mL (5.10 mM); Clear solution

This protocol yields a clear solution of ≥ 1.93 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (19.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 3

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.93 mg/mL (5.10 mM); Clear solution

This protocol yields a clear solution of ≥ 1.93 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (19.3 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Pureza y Documentación

Purity: 99.91%

Select Batch:

Ficha de datos (277 KB) SDS (393 KB)

COA (252 KB) HNMR (271 KB) RP-HPLC (243 KB) LCMS (102 KB)

Instrucciones de manejo (2659 KB)

Referencias

[1]. Bärfacker L, et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012;7(8):1385-1403. [Content Brief]

[2]. González-Blázquez R, et al. Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress. Front Pharmacol. 2018;9:1131. Published 2018 Oct 9. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.6426 mL	13.2128 mL	26.4257 mL	66.0642 mL
	5 mM	0.5285 mL	2.6426 mL	5.2851 mL	13.2128 mL
	10 mM	0.2643 mL	1.3213 mL	2.6426 mL	6.6064 mL
	15 mM	0.1762 mL	0.8809 mL	1.7617 mL	4.4043 mL
	20 mM	0.1321 mL	0.6606 mL	1.3213 mL	3.3032 mL
	25 mM	0.1057 mL	0.5285 mL	1.0570 mL	2.6426 mL
	30 mM	0.0881 mL	0.4404 mL	0.8809 mL	2.2021 mL
	40 mM	0.0661 mL	0.3303 mL	0.6606 mL	1.6516 mL
	50 mM	0.0529 mL	0.2643 mL	0.5285 mL	1.3213 mL
	60 mM	0.0440 mL	0.2202 mL	0.4404 mL	1.1011 mL
	80 mM	0.0330 mL	0.1652 mL	0.3303 mL	0.8258 mL
	100 mM	0.0264 mL	0.1321 mL	0.2643 mL	0.6606 mL

Finerenone Related Classifications

Metabolic Disease Cardiovascular Disease

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Finerenone1050477-31-0BAY 94-8862Mineralocorticoid Receptortype2diabeteschronickidneydiseasesystolicbloodpressureoralnonsteroidalcardiorenalInhibitorinhibitorinhibit

Productos vistos recientemente:

Nombre del producto

Requested Quantity *

Nombre del solicitante *

Saludo

Direcciòn del E-mail *

Número de teléfono *

Department

Nombre de la Organizaciòn *

City

Provincia

Country or Region *

Observaciones

Nombre del producto

Lot #

Nombre del solicitante *

Direcciòn del E-mail *

Número de teléfono

Department *

Nombre de la Organizaciòn *

Country or Region *

Observaciones

Name
E-mail *

	Sorry, but the email address you supplied was invalid.

Finerenone (Synonyms: BAY 94-8862)

Revisión del cliente

Other Forms of Finerenone:

Finerenone Related Antibodies

7 Publications Citing Use of MCE Finerenone

Recomendaciones destacadas

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Actividad biológica

Pureza y Documentación

Referencias

Revisión del cliente

Calculadora de molaridad

Calculadora de dilución

Complete Stock Solution Preparation Table

Finerenone Related Classifications

Keywords:

Productos vistos recientemente:

Revisión del cliente

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report